Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model
- PMID: 38589905
- PMCID: PMC11003129
- DOI: 10.1186/s40478-024-01763-6
Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model
Abstract
In malignant glioma, cytotoxic drugs are often inhibited from accessing the tumor site due to the blood-tumor barrier (BTB). Ibrutinib, FDA-approved lymphoma agent, inhibits Bruton tyrosine kinase (BTK) and has previously been shown to independently impair aortic endothelial adhesion and increase rodent glioma model survival in combination with cytotoxic therapy. Yet additional research is required to understand ibrutinib's effect on BTB function. In this study, we detail baseline BTK expression in glioma cells and its surrounding vasculature, then measure endothelial junctional expression/function changes with varied ibrutinib doses in vitro. Rat glioma cells and rodent glioma models were treated with ibrutinib alone (1-10 µM and 25 mg/kg) and in combination with doxil (10-100 µM and 3 mg/kg) to assess additive effects on viability, drug concentrations, tumor volume, endothelial junctional expression and survival. We found that ibrutinib, in a dose-dependent manner, decreased brain endothelial cell-cell adhesion over 24 h, without affecting endothelial cell viability (p < 0.005). Expression of tight junction gene and protein expression was decreased maximally 4 h after administration, along with inhibition of efflux transporter, ABCB1, activity. We demonstrated an additive effect of ibrutinib with doxil on rat glioma cells, as seen by a significant reduction in cell viability (p < 0.001) and increased CNS doxil concentration in the brain (56 ng/mL doxil alone vs. 74.6 ng/mL combination, p < 0.05). Finally, Ibrutinib, combined with doxil, prolonged median survival in rodent glioma models (27 vs. 16 days, p < 0.0001) with brain imaging showing a - 53% versus - 75% volume change with doxil alone versus combination therapy (p < 0.05). These findings indicate ibrutinib's ability to increase brain endothelial permeability via junctional disruption and efflux inhibition, to increase BTB drug entry and prolong rodent glioma model survival. Our results motivate the need to identify other BTB modifiers, all with the intent of improving survival and reducing systemic toxicities.
Keywords: Blood-tumor barrier; Doxil; Endothelial cells; Glioma; Ibrutinib.
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Enhancement in blood-tumor barrier permeability and delivery of liposomal doxorubicin using focused ultrasound and microbubbles: evaluation during tumor progression in a rat glioma model.Phys Med Biol. 2015 Mar 21;60(6):2511-27. doi: 10.1088/0031-9155/60/6/2511. Epub 2015 Mar 6. Phys Med Biol. 2015. PMID: 25746014 Free PMC article.
-
Adenosine A2A Receptor Activation Enhances Blood-Tumor Barrier Permeability in a Rodent Glioma Model.Mol Cancer Res. 2021 Dec;19(12):2081-2095. doi: 10.1158/1541-7786.MCR-19-0995. Epub 2021 Sep 14. Mol Cancer Res. 2021. PMID: 34521765 Free PMC article.
-
Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy.Cell Stem Cell. 2017 Nov 2;21(5):591-603.e4. doi: 10.1016/j.stem.2017.10.002. Cell Stem Cell. 2017. PMID: 29100012 Free PMC article.
-
Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.Expert Opin Emerg Drugs. 2020 Mar;25(1):25-35. doi: 10.1080/14728214.2020.1724282. Epub 2020 Feb 6. Expert Opin Emerg Drugs. 2020. PMID: 31996046 Review.
-
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.Blood Cancer J. 2021 Apr 29;11(4):79. doi: 10.1038/s41408-021-00467-7. Blood Cancer J. 2021. PMID: 33927183 Free PMC article. Review.
Cited by
-
The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials.Front Oncol. 2024 Sep 27;14:1454370. doi: 10.3389/fonc.2024.1454370. eCollection 2024. Front Oncol. 2024. PMID: 39399167 Free PMC article. Review.
References
-
- van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updates Rev Comment Antimicrob Anticancer Chemotherapy. 2015;19:1–12. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources